Iron infusion therapy is a popular strategy to treat severe iron deficiency, but it can cause significant hypophosphataemia in some patients.
Despite the growing number of case reports, this side effect is not well known to healthcare professionals. Clinicians should remain alert to the possibility of hypophosphatemia, particularly in patients who have regular IV iron.
During the webcast on 7 December, nephrologist, Prof Lawrence McMahon will go through which iron preparations commonly cause hypophosphatemia and outline the use of alternative IV iron products in patients who have risk factors for, or a history of hypophosphatemia, and describe the symptoms to look out for in your post-infusion patients to correct hypophosphatemia.
Attendees will be eligible for:
RACGP: 4 CPD activity points
ACRRM: 2 hours under the educational activities category
Don’t miss out, REGISTER NOW.
The Latest Covid Update
Prof Mary-Louise McLaws – Epidemiologist; Director, Immunisation Coalition; Professor of Epidemiology, Healthcare Infection and Infectious Diseases Control, UNSW
As vaccination rates around Australia peak, and the country begins to open up, what will be the new challenges as far as this pandemic goes? In this presentation, a leading expert will bring the latest information with regard to what health professionals need to know. The face of Covid is changing and all primary health providers need to ensure they continue to be up-to-date and well-informed.
Hypophosphataemia Associated with IV Iron Infusions – Should we be Concerned?
Prof Lawrence McMahon – Nephrologist; Executive Clinical Director, Specialty Medicine, Eastern Health, Victoria
Iron infusion therapy is increasingly popular as a strategy to treat severe iron deficiency. However, it is increasingly recognised that IV iron can also occasionally cause significant hypophosphataemia in some patients. Despite the growing number of case reports, this side effect is not well known to healthcare professionals. Clinicians should remain alert to the possibility of hypophosphatemia, particularly in those who have IV iron regularly. It appears to be more common with certain IV iron preparations. Suspect it if your post-infusion patient complains of symptoms such as weakness, bone pain, or a change in mental state. In such patients, serum phosphate should be measured and hypophosphatemia corrected. Consideration should also be given to the use of alternative IV iron products in patients who have risk factors for or a history of hypophosphatemia.
CBD Dominant Medicinal Cannabis Products: A Therapeutic Update
Prof Iain McGregor – Professor of Psychopharmacology, Academic Director, The Lambert Initiative for Cannabinoid Therapeutics, University of Sydney
There has been a major increase in the prescribing of medicinal cannabis (MC) over the past 2 years, particularly in the treatment of chronic pain, anxiety and sleep related disorders. This presentation will provide a state-of-the-art overview of MC in Australia including recent developments in the evidence base and key differences between tetrahydrocannabinol (THC) and cannabidiol (CBD) containing products. The key questions that patients have for their doctors will also be addressed, namely, how to access MC, how much it costs and if it is safe to drive while using MC products. This presentation will be of value to doctors who are considering medicinal cannabis prescribing or looking to update previous prescribing skills.
COPD Triple Therapy – Pros & Cons
Prof Christine Jenkins – Clinical Professor University of Sydney, Thoracic Physician Concord Hospital, Head Respiratory Trials, George Institute
In the past, COPD has been a very depressing diagnosis, as traditionally the progression to severe breathlessness and disability has seemed relentless and inevitable. Now, as COPD expert, Prof Jenkins explains, so much more can be done. This comprehensive presentation will cover the most current, evidence-based recommendations across all areas of the condition from diagnosis to management and treatment which can help change the trajectory for those patients with severe COPD.
PLEASE NOTE: Due to the high levels of traffic we experience and the new log in process to our website, please make sure you log in to the website 15 minutes prior to the start of the webcast to ensure that your viewing is not disrupted.
Tuesday 7th December
7:00pm – 9:300pm AEDT (NSW, VIC, TAS, ACT, QLD)
6pm – 8:30pm AEST (QLD)
6:30pm – 9pm ACDT (SA)
5:30pm – 8pm ACST (NT)
4pm – 6:30pm AWST (WA)